Docetaxel vs Surveillance After Radical Radiotherapy for Intermediate- or High-Risk Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-Risk Prostate Cancer-Results From the Prospective, Randomised, Open-Label Phase III SPCG-13 Trial
Eur Urol 2019 Aug 20;[EPub Ahead of Print], PL Kellokumpu-Lehtinen, M Hjälm-Eriksson, C Thellenberg-Karlsson, L Åström, L Franzen, AS Fransson, MJ Leskinent, M Zeke, T Huttunen, C GinmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.